The Kingdom of the Netherlands
and
the European Medicines Agency,
Having regard to the Treaty on the European Union, in particular Protocol No 7 on the Privileges and Immunities of the European Union annexed to the Treaty on the European Union (hereinafter “the Protocol”), the Treaty on the Functioning of the European Union and the Treaty establishing the European Atomic Energy Community;
Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency;
Having regard to the decision of the Member States in the margins of the General Affairs Council meeting of 20 November 2017 to relocate the seat of the European Medicines Agency in Amsterdam, the Netherlands;
Whereas Article 74 of Regulation (EC) No. 726/2004 provides that the Protocol shall apply to the Agency and to its staff;
Whereas Article 75 of Regulation (EC) No 726/2004 provides that the Staff Regulations of officials of the European Union, the Conditions of Employment of Other Servants of the European Union and the rules adopted jointly by the institutions of the European Union for the purposes of the application of those Staff Regulations and Conditions of Employment shall apply to the staff of the Agency;
Whereas further administrative provisions must be agreed for the implementation of the Protocol, in particular to lay down conditions concerning the privileges, immunities, facilities, and services of and related to the Agency and its staff in the territory of the Kingdom of the Netherlands as necessary for the fulfilment of the purposes of the Agency;
Have agreed as follows: